182 related articles for article (PubMed ID: 24164271)
1. IMAP 2012: Antimicrobial peptides to combat (multi)drug-resistant pathogens.
Adermann K; Hoffmann R; Otvos L
Protein Pept Lett; 2014 Apr; 21(4):319-20. PubMed ID: 24164271
[No Abstract] [Full Text] [Related]
2. Using adjuvants and environmental factors to modulate the activity of antimicrobial peptides.
Walkenhorst WF
Biochim Biophys Acta; 2016 May; 1858(5):926-35. PubMed ID: 26751595
[TBL] [Abstract][Full Text] [Related]
3. The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation.
Park SC; Park Y; Hahm KS
Int J Mol Sci; 2011; 12(9):5971-92. PubMed ID: 22016639
[TBL] [Abstract][Full Text] [Related]
4. Omiganan pentahydrochloride in the front line of clinical applications of antimicrobial peptides.
Melo MN; Dugourd D; Castanho MA
Recent Pat Antiinfect Drug Discov; 2006 Jun; 1(2):201-7. PubMed ID: 18221145
[TBL] [Abstract][Full Text] [Related]
5. [Advances in the research of treating multi-drug resistant bacterial infections].
Peng Y; Fu YX
Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):539-41. PubMed ID: 27647070
[TBL] [Abstract][Full Text] [Related]
6. [Biological alternatives to antibiotics].
Sliwa-Dominiak J; Witkowska M; Deptuła W
Przegl Epidemiol; 2010; 64(3):399-403. PubMed ID: 20976953
[TBL] [Abstract][Full Text] [Related]
7. An overview of antimicrobial peptides and the latest advances in their development.
Sierra JM; Fusté E; Rabanal F; Vinuesa T; Viñas M
Expert Opin Biol Ther; 2017 Jun; 17(6):663-676. PubMed ID: 28368216
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial peptides stage a comeback.
Fox JL
Nat Biotechnol; 2013 May; 31(5):379-82. PubMed ID: 23657384
[No Abstract] [Full Text] [Related]
9. Integrated evolutionary analysis reveals antimicrobial peptides with limited resistance.
Spohn R; Daruka L; Lázár V; Martins A; Vidovics F; Grézal G; Méhi O; Kintses B; Számel M; Jangir PK; Csörgő B; Györkei Á; Bódi Z; Faragó A; Bodai L; Földesi I; Kata D; Maróti G; Pap B; Wirth R; Papp B; Pál C
Nat Commun; 2019 Oct; 10(1):4538. PubMed ID: 31586049
[TBL] [Abstract][Full Text] [Related]
10. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Lipsky BA; Holroyd KJ; Zasloff M
Clin Infect Dis; 2008 Dec; 47(12):1537-45. PubMed ID: 18990064
[TBL] [Abstract][Full Text] [Related]
11. Iseganan. IB 367, protegrin IB 367.
Drugs R D; 2002; 3(1):52-5. PubMed ID: 11881532
[No Abstract] [Full Text] [Related]
12. Clinical potential of engineered cationic antimicrobial peptides against drug resistant biofilms.
Melvin JA; Montelaro RC; Bomberger JM
Expert Rev Anti Infect Ther; 2016 Nov; 14(11):989-991. PubMed ID: 27626708
[No Abstract] [Full Text] [Related]
13. Combating bacterial infections with host defense peptides: Shifting focus from bacteria to host immunity.
Gao N; Wang J; Fang C; Bai P; Sun Y; Wu W; Shan A
Drug Resist Updat; 2024 Jan; 72():101030. PubMed ID: 38043443
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial peptides: potential use in skin infections.
Ulvatne H
Am J Clin Dermatol; 2003; 4(9):591-5. PubMed ID: 12926977
[TBL] [Abstract][Full Text] [Related]
15. Fighting bacterial infections-future treatment options.
Fernebro J
Drug Resist Updat; 2011 Apr; 14(2):125-39. PubMed ID: 21367651
[TBL] [Abstract][Full Text] [Related]
16. Novel antimicrobial peptide CPF-C1 analogs with superior stabilities and activities against multidrug-resistant bacteria.
Xie J; Zhao Q; Li S; Yan Z; Li J; Li Y; Mou L; Zhang B; Yang W; Miao X; Jiang X; Wang R
Chem Biol Drug Des; 2017 Nov; 90(5):690-702. PubMed ID: 28371431
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of host defense peptides in antibiotic-resistant infections.
Afacan NJ; Yeung AT; Pena OM; Hancock RE
Curr Pharm Des; 2012; 18(6):807-19. PubMed ID: 22236127
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional antimicrobial peptides: therapeutic targets in several human diseases.
Zaiou M
J Mol Med (Berl); 2007 Apr; 85(4):317-29. PubMed ID: 17216206
[TBL] [Abstract][Full Text] [Related]
19. Cationic antimicrobial peptides in clinical development, with special focus on thanatin and heliomicin.
Andrès E
Eur J Clin Microbiol Infect Dis; 2012 Jun; 31(6):881-8. PubMed ID: 21964560
[TBL] [Abstract][Full Text] [Related]
20. Host defense peptides for use as potential therapeutics.
Zhang L; Falla TJ
Curr Opin Investig Drugs; 2009 Feb; 10(2):164-71. PubMed ID: 19197794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
